Dr Zohar Koren – FSD Pharma

Dr Zohar Koren

Head of Scientific Advisory Board

Dr. Koren is co-founder and CEO of SciCann Therapeutics Inc., a Canadian-Israeli speciality pharmaceutical firm dedicated to the development of cutting edge technologies in the pharmaceutical cannabinoid space. Prior to that, Dr. Koren served as VP BD of Mor Research Applications, the technology transfer office of Clalit Healthcare Services, Israel’s largest medical insurer and healthcare provider. He also served as VP BD of Talent Biotechs, a pharmaceutical company which developed CBD based therapies for GVHD (Graft Vs Host Disease), until its acquisition by Kalytera Inc. in 2017. Previously, Dr. Koren served as Co-founder, CEO and CFO of Cannabics Pharmaceuticals Inc. (OTCQB:CNBX), a developer of cannabis based therapies for oncology patients, and prior to that as Director of Business Development at Aposense Ltd (TASE:APOS), a developer of novel pharmaceutical products in the oncology, CNS and metabolic disease fields.

Dr. Koren holds a Ph.D. and M.Sc. in Protein science and computational biology from the University of Haifa, and a B.Sc. in Mathematics, Physics and Biology from the Hebrew University in Jerusalem. Dr. Koren is a veteran of the prestigious “Talpiyot” program of the Israeli Defence Forces, an elite unit designed to qualify the top technology officers of the IDF.